Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

At baseline, ctDNA positivity predicted worse two-year EFS in both arms, yet EV+Pembro still outperformed chemotherapy in positive and negative patients. The hosts found no predictive signal, and ctDNA-negative patients on chemotherapy still faced roughly 15–20% relapse risk, so baseline results should not guide de-escalation.

Related Insights

While trials like IMvigor011 show ctDNA can guide adjuvant immunotherapy after surgery, this data may not apply to the new standard of care. With neoadjuvant EV/pembrolizumab becoming prevalent, the prognostic and predictive value of post-operative ctDNA is now unknown, requiring new prospective studies.

Circulating tumor DNA (ctDNA) provides more actionable risk stratification than pathologic stage in resected upper tract disease. Patients who test ctDNA negative exhibit a low 20% to 30% risk of recurrence, making active surveillance reasonable to avoid toxic, marginally effective adjuvant therapies. Conversely, ctDNA positivity behaves like occult metastatic disease with recurrence rates approaching 95%, prompting clinicians to bypass adjuvant platinum for full-dose enfortumab vedotin plus pembrolizumab.

John Chatzko reported that 82% of baseline ctDNA-positive patients cleared ctDNA before surgery on EV+Pembro versus 67% on gem/cis. Among those clearers, two-year EFS was 81% versus 63%, suggesting EV+Pembro drives a deeper biologic response. That gap implies the quality, not just frequency, of clearance differs by regimen.

Unlike immunotherapy, where ctDNA clearance strongly predicts good outcomes, chemotherapy can cause a temporary decrease in ctDNA that doesn't correlate with long-term survival. This "smudging" effect complicates ctDNA interpretation for patients receiving chemo-immunotherapy combinations.

Tom said no pre-surgery ctDNA-positive patient achieved pCR in EV304 or Niagara. Among ctDNA-negative patients, pCR was 75% with EV+Pembro but roughly 50-50 with chemotherapy. That makes bladder-sparing risky while ctDNA remains positive; the test is not a green light for less local therapy.

While adjuvant immunotherapy benefits ctDNA-positive patients, it may not be the optimal strategy. Given their near-certainty of relapse (95%), using a single-agent immunotherapy when a more potent combination like EV-Pembro exists for metastatic disease raises the critical question of whether these high-risk patients are being undertreated.

For ctDNA-positive patients with high relapse risk, a clinical conflict arises. 'Purists' advocate for treatments with prospective trial data (single-agent immunotherapy), while 'pragmatists' argue for using the most effective therapy available (like EV pembro), treating ctDNA positivity as early metastatic disease, even without specific trial evidence in that setting.

A critical warning for clinicians: data showing that ctDNA-negative patients can skip *adjuvant* therapy (InVigor011) should not be extrapolated to the *neoadjuvant* setting. Stopping the post-operative portion of a perioperative EV-Pembro regimen based on a negative ctDNA result is unsupported by data and risks under-treating patients.

Observational data from the BESPOKE study showed that the survival benefit from adjuvant chemotherapy was only seen in patients who tested positive for ctDNA post-surgery. In contrast, ctDNA-negative patients had overlapping survival curves whether they received chemotherapy or not, questioning its utility for that group.

Tom noted 24-month EFS was 94% in EV+Pembro patients who were ctDNA-negative at baseline and stayed negative, but John Chatzko cautioned that about a quarter of pre-surgery ctDNA-negative EV+Pembro patients still lacked pCR. They favored randomized de-escalation trials over routine treatment reduction; the high survival is real, but causal attribution is not.